MAGNESIUM SULPHATE INJECTION BP MINIJET, 50% w/v
Read all of this leaflet carefully.
Keep this leaflet. You may need to read it again. If you have further questions, please ask your doctor or nurse. This medicine has been prescribed for you personally and you should not pass it on to others. It may harm them, even if their symptoms are the same as yours.
In this leaflet:
- 1. What Magnesium Sulphate is and what it is used for
- 2. Before you are given Magnesium Sulphate Injection
- 3. How Magnesium Sulphate Injection is used
- 4. Possible side effects
- 5. Storing Magnesium Sulphate Injection
Marketing Authorisation Holder is
Manufacturer:
What Magnesium Sulphate is and what it is used for
Your medicine is called Magnesium Sulphate Injection BP Minijet, 50% w/v. It is a sterile solution for injection and contains 500mg or 2mmols of magnesium sulphate (the active ingredient) in each ml of injection. It also contains sodium hydroxide, sulphuric acid and water for injections. It is available as a 4ml vial.
Magnesium sulphate belongs to a group of medicines called mineral supplements.
Magnesium Sulphate Injection BP Minijet, 50% w/v is used to treat magnesium deficiency (lack of magnesium), where it is not possible for the medicine to be taken by mouth. This could be due to malabsorption, severe diarrhoea, chronic alcoholism, malnutrition or having to have all nutrients by injection.
Before you are given Magnesium Sulphate Injection
Before being given Magnesium Sulphate Injection your doctor will have decided that it was absolutely vital that you have it. However, please tell your doctor if the answers to any of the following questions are YES, as he or she may want to give you special advice or alter your treatment.
- Are you suffering from any form of heart disease, for example, have you had a heart attack or heart block (where your heart beat signals are delayed)?
- Do you suffer from poor kidney function?
- Are you pregnant, likely to be pregnant, or breast feeding?
Taking other medicines:
- Are you receiving drugs for heart disease called cardiac glycosides, e.g. digitoxin?
- Have you been prescribed any of the following medicines: opioids (e.g. morphine); barbiturates (e.g. amylobarbitone); or hypnotics (e.g. nitrazepam)?
- Are you going to have an anaesthetic where a muscle relaxant will be used?
How much will I be given
Magnesium sulphate is injected into a muscle or a vein, as directed by the doctor. For injection into a vein, the solution should be diluted to 20% or less, and the rate of injection should be less than 1.5ml per minute of a 10% solution. In children the solution should also be diluted to 20% if being injected into a muscle.
For mild magnesium deficiency the usual dose is 1 gram every 6 hours for 4 doses injected into a muscle.
For severe magnesium deficiency up to 250 milligrams per kilogram of body weight may be injected into a muscle every 4 hours, or 5 grams per litre of solution is given intravenously as an infusion over 3 hours.
If you think you have been given too much of this medicine, tell your doctor immediately.
Signs of too much magnesium include flushing, thirst, drowsiness, confusion, muscle weakness, loss of reflexes, slow and/or shallow breathing, low blood pressure and irregular heartbeat.
Possible side effects
Side effects after use are usually a sign that your body has now got more than enough or too much magnesium. These include:
- respiratory depression (slow and/or shallow breathing)
- flushing
- thirst
- low blood pressure
- drowsiness
- confusion
- loss of reflexes
- muscle weakness
- irregular hearbeat
If you think this medicine has upset you in any way please tell your doctor.
Storing Magnesium Sulphate injection
Do not store above 25°C. Store in the original container and keep the container in the outer carton.
This medicine should not be used after the expiry date shown on the pack.
KEEP THIS AND ALL MEDICINES OUT OF THE REACH AND SIGHT OF CHILDREN.
This leaflet only applies to the product (Magnesium Sulphate Injection BP Minijet, 50% w/v) for which it has been prepared.
Date of preparation of leaflet: May 2002
P1057A
No comments:
Post a Comment